Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TN-1001
- Development stage
- Preclinical
- Lead developer
- TransGenex Nanobiotech
- Modality
- Gene Therapies
01
Overview
TN-1001 is a preclinical gene therapy candidate developed by TransGenex Nanobiotech for the treatment of ovarian cancer. Identified using the company's proprietary Functional in-vivo Stem cell Screening (FiSS) platform, the drug is designed to target and inhibit cancer stem cells (CSCs). Its mechanism of action involves the inhibition of specific signaling pathways that regulate the interactions between tumor cells and the surrounding stroma, thereby disrupting the maintenance and self-renewal of the CSC population. As of the latest reports, TN-1001 has undergone testing in non-human primate models to evaluate its efficacy and safety in treating ovarian malignancies.
Beyond the preview
Go deeper on TN-1001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TN-1001.